Viropro Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VPRO research report →
Companywww.viropro.net
Viropro Inc. , through its subsidiaries, engages in the contract research, development, and manufacture of biotherapeutic proteins for the treatment of various diseases. The company is also involved in the transfer of its proprietary technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases, such as cancer, diabetes, hepatitis, or multiple sclerosis.
- CEO
- Michelle Leanne Edythe Peake
- IPO
- 1995
- HQ
- San Jose, CA, US
Price Chart
Valuation
- Market Cap
- $25.40K
- P/E
- -0.00
- P/S
- 0.04
- P/B
- 0.00
- EV/EBITDA
- -0.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -174.49%
- Net Margin
- -176.88%
- ROE
- -185.71%
- ROIC
- 0.00%
Growth & Income
- Revenue
- $571.10K · 0.00%
- Net Income
- $-1,010,149 · 31.04%
- EPS
- $-0.01 · 0.00%
- Op Income
- $-996,515
- FCF YoY
- 6.92%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 3.61
- Avg Volume
- 42.99K
Get TickerSpark's AI analysis on VPRO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our VPRO Coverage
We haven't published any research on VPRO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VPRO Report →